Intensity Therapeutics (INTS) Set to Release Quarterly Earnings on Thursday

Intensity Therapeutics (NASDAQ:INTS) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.94) per share for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Intensity Therapeutics (NASDAQ:INTS) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.24). On average, analysts expect Intensity Therapeutics to post ($2.64) EPS for the current fiscal year and ($1.67) EPS for the next fiscal year.

Intensity Therapeutics Price Performance

INTS opened at $3.41 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 5.00. The stock has a market capitalization of $11.13 million, a P/E ratio of -0.96 and a beta of 2.81. The company’s 50 day simple moving average is $3.74 and its 200-day simple moving average is $5.25. Intensity Therapeutics has a one year low of $3.00 and a one year high of $17.68.

Wall Street Analyst Weigh In

A number of research analysts have commented on INTS shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Monday, October 19th. Citigroup restated a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th. Finally, HC Wainwright upped their price target on Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc (NASDAQ: INTS) is a clinical-stage biotechnology company developing investigational cancer immunotherapies designed to treat solid tumors. Its approach focuses on injecting therapies directly into tumors to promote tumor-cell destruction and stimulate a broader immune response against cancer.

The company’s lead product candidate, INT230-6, is a proprietary formulation containing the chemotherapy agents cisplatin and vinblastine combined with an amphiphilic delivery agent.